1 December 2021
On the occasion of World AIDS Day 2021, MPP recorded the thoughts & hopes of its partners in South Africa, many of whom are working on the mRNA vaccine Technology Transfer hub. At MPP we share the hope that this technology will one day provide the world with an effective HIV vaccine.
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Japanese Government, and the Swiss Agency for Development and Cooperation.
